ClinicalTrials.gg
Not yet recruitingNCT07943754FORTIFYUpdated Nov 17, 2026

Fighting Osteoporosis With Risedronate Co-Therapy During Incretin

A Phase 3 interventional study of Tirzepatide and Risedronate in Obesity, sponsored by Wake Forest University Health Sciences. Not yet recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Wake Forest University Health Sciences · Phase 3, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Obesity by Wake Forest University Health Sciences — 4 open to participants now, 5 under way, 2 of them phase 3. Obesity · Wake Forest University Health Sciences.

Planned enrollment
19th of 40
96 · median 88
Started
2027
the only one that year
Phase 3
2 of 46
2 open now
Registered
46th of 46
by date

Among the 46 studies in Obesity by Wake Forest University Health Sciences, this one is the 19th largest by planned enrollment of the 40 interventional ones that give a count, is the only one that started in 2027, is one of 2 in phase 3, and was the 46th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 46 studies in Obesity by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Obesity by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

Tirzepatide produces rapid, clinically meaningful weight loss. In older adults, however, substantial weight reduction may accelerate loss of bone and muscle, increase frailty risk, and compound age-related skeletal vulnerability. The purpose of this study is to find out if taking risedronate along with tirzepatide preserves musculoskeletal health during tirzepatide-associated weight loss.

Read the detailed description

Tirzepatide produces rapid, clinically meaningful weight loss. Weight loss of this magnitude is accompanied by increased bone turnover, hip bone loss, and loss of fat-free mass. Risedronate is a bisphosphonate therapy that inhibits osteoclast-mediated bone resorption and has an established monthly oral regimen. Pilot bariatric-surgery data from the investigative team support feasibility [1], attenuation of bone loss and resorption [2], and a signal for preservation of appendicular lean mass [3]. This single-center, 12-month, randomized, double-blind, placebo-controlled, parallel-group phase 3 clinical trial evaluates the premise that risedronate will blunt the skeletal consequences of tirzepatide-associated weight loss and may secondarily preserve muscle through bone-muscle signaling pathways.

03

Conditions studied

  • Obesity

Keywords

  • obesity treatment
  • bone loss
  • older adults
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥30 or 27.0-29.9 kg/m2 plus one weight related co-morbidity
  • Weight stability (within 5% in past 3 months)
  • Community dwelling
  • English speaking
  • Able to attend regular in person appointments, willingness to take tirzepatide and risedronate medication, and willing to provide

Exclusion criteria

Exclusion Criteria:

  • Weight >450 lbs (DXA limit)
  • Disordered alcohol or substance use
  • Eating disorder in past 5 years
  • >1 fall (injurious or non-injurious) in past year or prior fragility fracture
  • Osteoporosis (self-report, medication use, or T-score ≤ -2.5 on hip or spine DXA scan)
  • Use of oral (>5 d/month in past 3 months), use of incretin analog (GLP1Ra or dual agonist) in past 24 months, use of any AOM or prescription osteoporosis medication in last 12 months, history of intolerance or adverse reaction to GLP1Ra (other incretin analog) or bisphosphonate, concomitant use of insulin secretagogues or insulin
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Tirzepatide Plus Risedronate

    Drug: Tirzepatide · Drug: Risedronate

  • Active comparator
    Tirzepatide Plus Placebo

    Drug: Tirzepatide · Other: Placebo

Interventions

  • DrugTirzepatide

    Tirzepatide 2.5 mg weekly for 4 weeks, then 5 mg, 7.5 mg, and 10 mg at 4-week intervals as tolerated; continue 10 mg weekly through month 12.

  • DrugRisedronate

    Risedronate 150 mg orally once monthly for 12 doses

  • OtherPlacebo

    risedronate matching placebo orally once monthly for 12 doses

06

What researchers measure

Primary outcomes

  1. Change in Hip Bone Mineral Density

    change in total hip areal bone mineral density by DXA

    Time frame: from baseline to month 12

Secondary outcomes

  1. Appendicular Lean Mass

    appendicular lean mass by DXA

    Time frame: Month 6, Month 12

  2. Hip Bone Strength

    hip bone strength by QCT-derived finite element analysis

    Time frame: Month 6, Month 12

  3. Distal Tibia Trabecular Number

    distal tibia trabecular number by HR-pQCT

    Time frame: Month 6, Month 12

  4. Gait Speed

    fast-paced gait speed from the 400-m walk test

    Time frame: Month 6, Month 12

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2027; primary completion for Nov 2031, 53 months later.

Of 63 non-industry phase 3 interventional studies under Obesity, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 56. This study's planned 53 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Jun 2027
Primary completionEst.
Nov 2031
CompletionEst.
Nov 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07943754
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jun 2027 (estimated)
Primary completion
Nov 2031 (estimated)
Completion
Nov 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Kim Kennedy
Contact
Kimberly.Kennedy@Advocatehealth.org
336.713.8567
Ashley Weaver, PhD
principal investigator · Atrium Health Wake Forest Baptist

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion